Lewy Body Dementia Treatment Market: Introduction

Lewy body dementia (LBD) is the second-most common form of progressive dementia after Alzheimer’s disease. This is termed as dementia with protein deposits, known as Lewy bodies. These Lewy bodies are deposited in the region of the brain that is responsible for thinking, memory, and movement. Lewy body dementia causes a decline in mental abilities resulting in various symptoms such as visual hallucinations, rigid muscles, tremors, and slow movement. Other symptoms include poor regulation of body functions, cognitive problems, sleep difficulties, and depression.

Read Report Overview – https://www.transparencymarketresearch.com/lewy-body-dementia-treatment-market.html

LBD is the third-most common cause of dementia, thereby accounting for 5% to 10% of total cases. Lewy body is also estimated to be found in other brain disorders such as Alzheimer’s disease and Parkinson’s disease.

Key Drivers, Restraints and Opportunities of Global Lewy Body Dementia Treatment Market

Rise in geriatric population and presence of key players in the market launching the drugs for managing dementia condition are few factors propelling the global Lewy body dementia treatment market. As per research, 40% of Parkinson’s patients are likely to suffer from Parkinson’s dementia disease after the age of 60. In China, the geriatric population is estimated to increase by 30% by 2040. This is expected to drive the demand for efficient treatment of LBD during the forecast period.

Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78910

Robust research & development and investments in the same would drive the development of biologics and other advanced therapies for the management of LBD, which in turn is anticipated to propel the global market in the near future.

Lewy body dementia is a progressive disease which accounted for the 10% to 15% of the total cases of dementia. In the U.K., as per research, among 100 dementia patients, 10 to 15 patients suffer from LBD and hence, this statistic is estimated to boost the Lewy body dementia treatment market.

Underdiagnosis and late diagnosis of LBD in the geriatric population is likely to hinder the treatment for the same. Furthermore, there is no cure for LBD, which is estimated to be a key factor restraining the market.

Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78910

North America to Capture Major Share of Global Lewy Body Dementia Treatment Market

North America is expected to account fora major share of the global lewy body dementia treatment attributable to a rise in the geriatric population, an increase in prevalence of dementia, rise in patient burden suffering from Alzheimer’s and Parkinson’s diseases, and technological advancements. Moreover, presence of key market players; availability of drugs to manage LBD; awareness created by various companies, associations & governments; and well-established healthcare infrastructure are major factors boosting the market in the region. As per National Institute of Neurological Disorders and Strokes, in 2019, an estimated 1.4 million people in the U.S. are likely to suffer from lewy body dementia, which includes Parkinson’s disease dementia.

The Lewy body dementia treatment market in Asia Pacific is estimated to expand at a significant pace during the forecast period. Underdiagnosis of neurological conditions, such as dementia, Parkinson’s, and Alzheimer’s disease in the region, and an increase in the geriatric population in China, Japan, South Korea, and India are expected to augment the Lewy body dementia treatment market in Asia Pacific in the near future.

Pre Book Lewy Body Dementia Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=78910&ltype=S

Key Players Operating in Global Lewy Body Dementia Treatment Market

The global Lewy body dementia treatment market is highly fragmented with the presence of various key small- and medium-sized players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global lewy body dementia market are:

  • BioArctic AB
  • Eisai Co., Ltd.
  • Axovant Sciences Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd
  • Jazz Pharmaceuticals, Inc
  • Immungenetics AG
  • Noven Pharmaceuticals, Inc
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc
  • Bayer AG

More Trending Reports by Transparency Market Research –

Clinical Laboratory Services Market: https://www.prnewswire.com/news-releases/focus-on-patients-welfare-spurs-sales-in-clinical-laboratory-services-market-mounting-burden-of-infectious-diseases-present-potential-revenue-streams-tmr-301331485.html

Myasthenia Gravis Market: https://www.prnewswire.com/news-releases/continual-medical-research-for-improved-treatment-underscores-growth-in-myasthenia-gravis-market-growth-projected-at-notable-8-cagr-through-2027-tmr-301334546.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

LEAVE A REPLY

Please enter your comment!
Please enter your name here